Valuation
- Market cap
- 11,545,300,000
- Revenue TTM
- $958,400,000
- Net income TTM
- $-288,280,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -30.08%
- Debt to equity
- 0.65
Trading
- Volume
- 289,200
- Avg volume
- 290,610
- Day's range
- $491.05 – $505.00
- Shares out
- 23,104,000
- Stochastic %K
- 22%
- Beta
- -1.04
- Analysts
- Strong Sell
- Price target
- $675.50
Company profile
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 267 824 2827
- Website
- https://www.madrigalpharma.com
- Address
- 1001 Conshohocken State Road, Suite 2-350, West Conshohocken, United States
Latest news
No headlines yet.
